Using low-dose magneto-thrombolysis to improve stroke treatment
Low-Dose Magneto-Thrombolysis to Expand Stroke Care
['FUNDING_SBIR_2'] · UNANDUP, LLC · NIH-10871913
This study is testing a new way to help people who have had a stroke by using tiny particles to make the standard treatment work better and faster, so more patients can safely receive the care they need.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNANDUP, LLC (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10871913 on ClinicalTrials.gov |
What this research studies
This research investigates a new approach to treating acute ischemic stroke (AIS) by using a novel nanoparticle-based thrombolysis platform that enhances the effectiveness of the standard drug alteplase. The goal is to safely accelerate the drug's action, potentially allowing more patients to benefit from thrombolysis, especially those who currently do not qualify due to risks associated with higher doses. By improving the safety and efficacy of this treatment, the research aims to increase the number of AIS patients who can receive timely and effective care. The study will involve clinical trials to evaluate the outcomes of this innovative treatment method.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing acute ischemic stroke, particularly those who are currently ineligible for standard thrombolysis due to safety concerns.
Not a fit: Patients with hemorrhagic strokes or those who do not have acute ischemic stroke will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve stroke outcomes and increase the number of patients who can safely receive thrombolysis treatment.
How similar studies have performed: While thrombolysis is a well-established treatment, this specific approach using low-dose magneto-thrombolysis is novel and has not been extensively tested in prior studies.
Where this research is happening
SAINT LOUIS, UNITED STATES
- UNANDUP, LLC — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CREIGHTON, FRANCIS MILTON — UNANDUP, LLC
- Study coordinator: CREIGHTON, FRANCIS MILTON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.